Evidence map›Paper›PMID 35332852›Full record

ArticleBioengineered2022

miR-125a attenuates the malignant biological behaviors of cervical squamous cell carcinoma cells through Rad51.

Zeping Liu, Jinchang Huang, Qiuju Jiang, Xiaoling Li, Xiaohui Tang, Shasha Chen, Liling Jiang, Genghua Fu, Sijun Liu

Open access · goldAbstract read
In one paragraph

Article in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. RAD51 Inhibition Shows Antitumor Activity in Hepatocellular Carcinoma.International journal of molecular sciences · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Zeping LiuDepartment of Pathology, The Second Hospital of Longyan, Longyan, China.
Jinchang HuangDepartment of Pathology, Ganzhou People's Hospital, the Affiliated Ganzhou Hospital of Nanchang University, Ganzhou, China.
Qiuju JiangDepartment of Pathology, The Second Hospital of Longyan, Longyan, China.
Xiaoling LiDepartment of Pathology, The Second Hospital of Longyan, Longyan, China.
Xiaohui TangDepartment of Pathology, The Second Hospital of Longyan, Longyan, China.
Shasha ChenDepartment of Pathology, The Second Hospital of Longyan, Longyan, China.
Liling JiangDepartment of Gynaecology and Obstetrics, The Second Hospital of Longyan, Longyan, China.
Genghua FuDepartment of Gynaecology and Obstetrics, The Second Hospital of Longyan, Longyan, China.
Sijun LiuDepartment of Pathology, The First Affiliated Hospital of Gannan Medical University, Gannan, China.
Longyan University · CNFirst Affiliated Hospital of Gannan Medical University · CNGanzhou People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical squamous cell carcinoma (CSCC), the most common cervical malignancy, is more likely to invade and metastasize than other cervical cancers. miR-125a, a tumor suppressor gene, has been confirmed to be associated with cancer metastasis. However, the role of miR-125a in CSCC and the underlying mechanism are unknown. miR-125a expression was confirmed by real-time quantitative PCR (RT-qPCR), and the Rad51 expression level was measured by western blotting analysis. CSCC cell proliferation, migration and invasion were assessed with functional assays, including CCK-8, colony formation, wound healing and Transwell assays. Our data confirmed that miR-125a is expressed at low levels in CSCC tissues and cells. Functionally, the overexpression of miR-125a greatly prevented the proliferation, migration and invasion of CSCC cells, and the inhibition of miR-125a expression strongly enhanced these behaviors in CSCC cells. Moreover, the expression of Rad51, a miR-125a target gene, greatly reversed the miR-125-mediated inhibition of CSCC cell proliferation, migration and invasion. In addition, we discovered that miR-125a downregulated the levels of phosphorylated PI3K, AKT and mTOR through Rad51 in CSCC cells. miR-125a, a tumor suppressor, can attenuate the malignant behaviors of CSCC cells by targeting Rad51. Therefore, the miR-125a/Rad51 axis might be a target for CSCC therapy.

Indexed as

Carcinoma, Squamous CellMicroRNAsRad51 RecombinaseUterine Cervical NeoplasmsCell Line, TumorCell MovementCell ProliferationFemaleHumansMicroRNAsMIRN125 microRNA, humanRAD51 protein, humanRad51 RecombinaseCervical squamous carcinomamicroRNA-125aPI3K/AktRad51

Identifiers

PMID35332852
PMCPMC9161904
OpenAlexW4220684920

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.